Show Summary Details
Page of

Biological therapies for immune, inflammatory, and allergic diseases 

Biological therapies for immune, inflammatory, and allergic diseases
Biological therapies for immune, inflammatory, and allergic diseases

John D. Isaacs

, and Nishanthi Thalayasingam

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2021. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 28 February 2021

Therapeutic monoclonal antibodies and related molecules are increasingly used to treat immune-mediated and inflammatory diseases. They interact very precisely with a soluble or cell-bound ligand to have three predominant effects: neutralization of proinflammatory cytokines or growth factors; modulation of intercellular interactions; or depletion of pathogenic cells. They deliver significantly enhanced specificity in comparison to traditional synthetic drugs and have delivered substantial improvements in clinical outcomes in many immune, inflammatory, and allergic diseases. However, there are no biomarkers to help decide which biological class to try first in a particular patient, hence one of the main challenges for the future is the identification of ‘stratifiers’ to guide therapy.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.